Neopterin is an independent prognostic variable in females with breast cancer

Clinical Chemistry

Volumn 45, Issue 11, 1999, Pages 1998-2004

  Murr, Christian ^a   Bergant, Anton ^a   Widschwendter, Martin ^a   Heim, Kurt ^a   Schröcksnadel, Hans ^a   Fuchs, Dietmar ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; NEOPTERIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER MORTALITY; CANCER STAGING; FEMALE; FOLLOW UP; HELPER CELL; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; PROGNOSIS; TUMOR DIFFERENTIATION; TUMOR VOLUME; URINALYSIS;

EID: 0032738333     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.11.1998     Document Type: Article

References (32)

1. 1. Gerstner GJ, Friedl HP. Breast cancer: morbidity and mortality in Austria. Descriptive epidemiology 1983-1987. Dtsch Med Wochenschr 1990;115:730-4.
2. 2. Schmidt F. Mammography. Acta Med Austriaca 1997;24:29-32.
3. 3. Erlichman C, Warde P, Gadalla T, Ciampi A, Baskerville T. RECPAM analysis of prognostic factors in patients with stage III breast cancer. Breast Cancer Res Treat 1990;16:231-42.
4. 4. Reuhl T, Kaisers H, Markwardt J, Haensch W, Hohenberger P, Schlag PM. Axillarausräumung bei klinisch nodal-negativem Mammakarzinom. Dtsch Med Wochenschr 1998;123:583-7.
5. 5. Dowset M. Improved prognosis for biomarkers in breast cancer. Lancet 1998;351:1753-4.
6. 6. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular activation in transplantation, inflammatory, infectious and malignant disease. Crit Rev Clin Chem 1992;29: 307-41.
7. 7. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection, Immunol Today 1988;9: 150-5.
8. 8. Fahey JL, Taylor JMG, Detels R, Hofmann B, Melmed R, Nishanian P, et al. The prognostic value of cellular and prognostic markers in infections with human immunodeficiency virus type I infection. N Engl J Med 1990;322:166-72.
9. 9. Reibnegger G, Egg D, Fuchs D, Günther G, Hausen A, Werner ER, et al. Urinary neopterin reflects clinical activity in patients with rheumatoid arthritis. Arthritis Rheum 1986;29:1063-70.
10. 10. Samsonov MY, Tilz GP, Egorova O, Reibnegger G, Balabanova RM, Nassonov EL, et al. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1995;4:29-32.
11. 11. Reibnegger G, Aichberger C, Fuchs D, Hausen A, Spielberger M, Werner ER, et al. Posttransplant neopterin excretion in renal allograft recipients: reliable diagnostic aid of acute rejection and predictive marker of long-term survival. Transplantation 1991;52: 58-63.
12. 12. Reibnegger G, Fuchs D, Fuith LC, Hausen A, Werner ER, Werner-Felmayer G, et al. Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect Prev 1991;15:483-90.
13. 13. Murr C, Berchtold J, Norer B, Waldhart E, Wachter H, Fuchs D. Neopterin as a prognostic parameter in patients with squamous cell carcinomas of the oral cavity. Int J Cancer Predict Oncol 1998;79:476-80.
14. 14. Wiegele J, Margreiter R, Huber C, Dworzak E, Fuchs D, Hausen A, et al. Urinary neopterin excretion in breast cancer patients. In: Pfleiderer W, Wachter H, Curtius H-C, eds. Biochemical and clinical aspects of pteridines, Vol. 3. Berlin: Walter de Gruyter, 1984:417-24.
15. 15. Rosen PP, Oberman H. Tumors of the mammary gland. In: Atlas of tumor pathology, 3rd series fascicle 7. Bethesda, MD: Armed Forces Institute of Pathology, 1992:115-7.
16. 16. Daxenbichter G, Forsthuber E-P, Marth C, Kemmter G, Wiegele J, Margreiter R, et al. Steroid hormone receptors and prognosis in breast cancer. Breast Cancer Res Treat 1988;12:267-73.
17. 17. Fuchs D, Werner ER, Wachter H. Soluble products of immune activation: neopterin. In: Rose NR, Conway de Macario E, Fahey JL, Friedman H, Penn GM, eds. Manual of clinical laboratory immunology. Washington, DC: American Society for Microbiology, 1992:251-5.
18. 18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
19. 19. Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972;34:187-220.
20. 20. Duffy MJ, Duggan C, Mulcahy HE, McDermott EW, O'Higgins NJ. Urokinase plasminogen activator: a prognostic marker in breast cancer including axillary node-negative disease. Clin Chem 1998;44:1177-83.
21. 21. Harbeck N, Dettmar P, Thomssen C, Henselmann B, Kuhn W, Ulm K, et al. Prognostic impact of tumor biological factors on survival in node-negative breast cancer. Anticancer Res 1998;18:2187-97.
22. 22. Brocklehurst D, Wilde CE, Finbow JA, Brett R, Champion AE, Dewhurst DG. Relative importance of estrogen and progesterone receptor assays as prognostic indicators in primary breast cancer: a short term study. Clin Chem 1989;35:238-40.
23. 23. Stierer M, Rosen H, Weber R, Hanak H, Auerbach L, Spona J, et al. A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer. Breast Cancer Res Treat 1995;36:11-21.
24. 24. Weiss G, Kronberger P, Conrad F, Bodner E, Wachter H, Reibnegger G. Neopterin and prognosis in patients with adenocarcinoma of the colon. Cancer Res 1993;53:260-5.
25. 25. Kronberger P, Weiss G, Tschmelitsch J, Fuchs D, Salzer GM, Wachter H, et al. Predictive value of urinary neopterin in patients with lung cancer. Eur J Clin Chem Clin Biochem 1995;33:831-7.
26. 26. Fuith LC, Dapunt O, Hetzel H, Reibnegger G, Wachter H. Second-look operation in women with ovarian cancer. I. Concentrations of neopterin in urine and CA 125 in serum at second-look laparotomy: their relationship with subsequent prognosis. Tumor Diagn Ther 1990;11:147-51.
27. 27. Shering SG, Sherry F, McDermott EW, O'Higgins NJ, Duffy MJ. Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma. Cancer 1998;83:2521-7.
28. 28. Fuchs D, Malkovsky M, Reibnegger G, Werner ER, Forni G, Wachter H. Endogenous release of interferon-gamma and diminished response of peripheral blood mononuclear cells to antigenic stimulation. Immunol Lett 1989;1990:23:103-8.
29. 29. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, et al. Neopterin modulates toxicity mediated by reactive oxygen and chlorine species. FEBS Lett 1993;321: 89-92.
30. 30. Murr C, Fuchs D, Gössler W, Hausen A, Reibnegger G, Werner ER, et al. Enhancement of hydrogen peroxide-induced luminol-dependent chemiluminescence by neopterin depends on the presence of iron chelator complexes. FEBS Lett 1994;338:223-6.
31. 31. Fuchs D, Baier-Bitterlich G, Wede I, Wachter H. Reactive oxygen and apoptosis. In: Scandalios J, ed. Oxidative stress and the molecular biology of antioxidant defenses. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1997:139-67.
32. 32. Überall F, Werner-Felmayer G, Schubert C, Grunicke HH, Wachter H, Fuchs D. Neopterin derivatives together with cyclic guanosine monophosphate induce c-fos gene expression. FEBS Lett 1994; 352:11-4.